NexImmune, Inc.

OTCPK:NEXI Stock Report

Market Cap: US$139.0

NexImmune Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure5yrs
Board average tenure5yrs

Recent management updates

Recent updates

Analysis Article • Sep 07

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Neximmune GAAP EPS of -$0.69 misses by $0.01

Neximmune press release (NASDAQ:NEXI): Q2 GAAP EPS of -$0.69 misses by $0.01. Shares +3.2% AH. Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related cancers Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22 Clinical updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 4Q22 Company is prioritizing resources to support Company’s lead product candidates, NEXI-001 and NEXI-003
Seeking Alpha • Jul 14

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune (NASDAQ:NEXI) stock jumped 23% postmarket on Thursday after the firm received investigational new drug clearance by FDA for its first cellular therapy candidate for solid tumors. NEXI-003, an autologous antigen-specific T cell product, is being developed for patients with relapsed or refractory HPV-related cancers. The IND clearance allows NEXI to begin phase 1 clinical trial to evaluate NEXI-003 for treatment of HPV-related cancers. The proposed study is a 2-part, multicenter, open-label, dose-finding, first-in-human study to evaluate safety and clinical activity of NEXI-003. "The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24-36 patients overall," NEXI said in a statement. After initial data and recommended phase 2 dose has been confirmed, NEXI plans to expand the NEXI-003 development program to include other HPV-related cancers and evaluate potential SOC combination options. NEXI stock has fallen 69% YTD.
Seeking Alpha • May 31

NexImmune: Selling For Under Cash Value

Shares of immune biopharma NexImmune have cratered 90% from their IPO pricing as early returns from two Phase 1/2 trials have failed to impress. In theory, the output from its AIM platform should improve upon CAR T therapies, as they are more specific and thus should be more effective and less toxic. Trading at a discount to cash, but with only enough to get NexImmune to 2Q23 (covering two data updates in 2H22), the recent purchases by three insiders merited further investigation. A full investment analysis follows in the paragraphs below.
Analysis Article • May 26

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 19

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

NexImmune has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
John Trainer
Consultant2.7yrsUS$1.35mno data
Karen Haslbeck
Head of Human Resourcesno datano datano data
Daniel Bednarik
Senior Vice President of Molecular Engineering & Protein Design9yrsno datano data
Robert Knight
Chief Medical Officer5.3yrsUS$2.91mno data
Chad Rubin
Senior Vice President of Corporate Affairs5.1yrsno datano data
Jack Ragheb
Senior Vice President of Translational Science4.8yrsno datano data
Matthew Schiller
Head of Business Development4.8yrsno datano data
5.0yrs
Average Tenure

Experienced Management: NEXI's management team is considered experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gerald Nepom
Chair of Autoimmune & Infectious Disease Scientific Advisory Board4.3yrsno datano data
Jeffrey Weber
Chief Scientific Advisor5yrsno datano data
Anil Rustgi
Member of Scientific Advisory Board5yrsno datano data
Jonathan Schneck
Co-Chairman of Scientific Advisory Board14.3yrsno datano data
Paul Richardson
Member of Scientific Advisory Boardno datano datano data
Marcela Maus
Member of Scientific Advisory Board5yrsno datano data
Miguel-Angel Perales
Member of Scientific Advisory Board5yrsno datano data
Kevan Herold
Member of Scientific Advisory Board and Autoimmune & Infectious Disease Scientific Advisory Board5yrsno datano data
Juan Varela
Member of Scientific Advisory Board5yrsno datano data
Michelle Krogsgaard
Member of Scientific Advisory Board5yrsno datano data
Yi Lin
Member of Scientific Advisory Board5yrsno datano data
Andreas Mackensen
Member of Scientific Advisory Board5yrsno datano data
5.0yrs
Average Tenure

Experienced Board: NEXI's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 03:02
End of Day Share Price 2026/05/26 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NexImmune, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kaveri PohlmanBTIG
Alethia YoungCantor Fitzgerald & Co.